Abstract: Distress models can be generated to model current or future deterioration of components. By correlating distress models with maintenance costs and material consumption, cumulative cost models and cumulative material models can be developed to optimize engine removal timing in order to maximize asset and portfolio value.

Abstract: Distress models can be generated to model current or future deterioration of components. By correlating distress models with maintenance costs and material consumption, cumulative cost models and cumulative material models can be developed to optimize engine removal timing in order to maximize asset and portfolio value.

Abstract: Provided herein are methods of using Syk inhibitors, such as a selective Syk inhibitor, Compound 1 or a pharmaceutically acceptable salt thereof, in treating allergic and/or inflammatory diseases or conditions of the eye. Also provided is pharmaceutical compositions, in particular eyedrop ophthalmic compositions, comprising Compound 1 or a pharmaceutically acceptable salt thereof, useful in the methods.

Abstract: Distress models can be generated to model current or future deterioration of components. By correlating distress models with maintenance costs and material consumption, cumulative cost models and cumulative material models can be developed to optimize engine removal timing in order to maximize asset and portfolio value.

Abstract: Systems and techniques for managing asset performance are presented. A system can generate a set of digital twin models indicative of a set of virtual representations for a set of physical components associated with an asset. The system can also generate a set of digital twin scores for the set of digital twin models. Furthermore, the system can determine a digital twin score indicative of a condition state for the asset based on the set of digital twin scores and a fly-forward forecasting model associated with predicted operational characteristics for the asset.

Abstract: Distress models can be generated to model current or future deterioration of components. By correlating distress models with maintenance costs and material consumption, cumulative cost models and cumulative material models can be developed to optimize engine removal timing in order to maximize asset and portfolio value.

Abstract: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

Abstract: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

Abstract: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

Abstract: The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.

Abstract: Provided are methods and compositions for treating and preventing dry eye and/or increasing tear film break-up time.

Abstract: The invention further features novel methods and compositions for treating and preventing dry eye by administration of neurotransmitters and/or neuropeptides, optionally in formulation with various other agents, as well as kits for the use of such novel formulations and methods.

Abstract: The invention features novel topical formulations of antiallergenic agents in formulation with various other agents (such as a tear substitute) that provide a comfortable formulation when instilled in the eye and has enhanced efficacy and duration of action. The invention further features novel methods of treating ocular allergy by topical application of antiallergenic agents in formulation with various other agents (such as a tear substitute), as well as kits for the use of such novel formulations and methods.